Magnesium Sulphate for Eclampsia and Fetal Neuroprotection: A Comparative Analysis of Protocols Across Canadian Tertiary Perinatal Centres.

J Obstet Gynaecol Can

Child and Family Research Institute, University of British Columbia, Vancouver BC; Department of Medicine, University of British Columbia, Vancouver BC; Department of Medicine, British Columbia Women's Hospital and Health Centre, Vancouver BC.

Published: November 2015

Background: Magnesium sulphate (MgSO4) has been recommended for fetal neuroprotection to prevent cerebral palsy, with national societies adopting new guidelines for its use. A knowledge translation project to implement Canadian guidelines is ongoing. Discussion about MgSO4 for fetal neuroprotection could not occur distinct from MgSO4 for eclampsia prophylaxis and treatment. Thus, in order to explore standardization of MgSO4 use in Canada, we sought to compare local protocols for eclampsia and fetal neuroprotection across tertiary perinatal centres.

Methods: Twenty-five Canadian tertiary perinatal centres were asked to submit their protocols for use of MgSO4 for eclampsia prophylaxis/treatment and fetal neuroprotection. Information abstracted included date of protocol, definitions of indications for treatment, details of MgSO4 administration, maternal and fetal monitoring, antidote for toxicity, and abnormal signs requiring physician attention. Descriptive analyses were used to compare site protocols with known definitions of preeclampsia. Data from the Canadian Perinatal Network (CPN) were used to verify what was done in clinical practice.

Results: Twenty-two of the 25 centres submitted protocols for eclampsia prevention/treatment. Eleven of these provided a definition of preeclampsia that warranted treatment; five of the 22 advised treatment of severe preeclampsia only. Criteria for treatment and monitoring procedures varied across centres. Sixteen of the 22 sites with protocols had data from the CPN. Of 635 women with pre-eclampsia, 422 (66.5%) received MgSO4. Twenty of 25 centres provided protocols for fetal neuroprotection. Definitions of indications were consistent across sites, except for gestational age cut-off.

Conclusion: This study suggests that local protocols are often inconsistent with published evidence. While this may be related to local institutional practices, relevant processes must be put in place to maximize uniformity of practice and improve patient care.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1701-2163(16)30047-0DOI Listing

Publication Analysis

Top Keywords

fetal neuroprotection
24
tertiary perinatal
12
magnesium sulphate
8
eclampsia fetal
8
protocols
8
canadian tertiary
8
perinatal centres
8
mgso4 eclampsia
8
local protocols
8
protocols eclampsia
8

Similar Publications

Objectives: Maternal protein malnutrition alters brain functioning, impairing fetal development. Physical exercise during gestation benefits the fetal organism from maternal adaptive changes that may be neuroprotective. This study evaluated the effect of a low-protein diet associated with maternal voluntary physical activity (VPA) on rats' behavioral and brain electrophysiological parameters in the mother-pup dyad.

View Article and Find Full Text PDF

Introduction: Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide. Treatments for TBI patients are limited and none has been shown to provide prolonged and long-term neuroprotective or neurorestorative effects. A growing body of evidence suggests a link between TBI-induced neuro-inflammation and neurodegenerative post-traumatic disorders.

View Article and Find Full Text PDF

Magnesium sulfate for fetal neuroprotection in preterm labor: an updated systematic review and meta-analysis of randomized controlled trials.

Arch Gynecol Obstet

December 2024

Unit of Obstetrics and Gynecology, "Paolo Giaccone" Hospital, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127, Palermo, Italy.

Objective: Antenatal magnesium sulfate has been reported to reduce the risk of neurological impairment in fetuses born to women at risk of preterm labor. However, the evidence to support its use is conflicting. We conducted this meta-analysis to assess the efficacy and safety of magnesium sulfate in women at risk of preterm labor as new research is available from RCTs giving insights into MgSO4 treatment among differing gestational age groups.

View Article and Find Full Text PDF

Oligodendrocyte Progenitor Cell Transplantation Reduces White Matter Injury in a Fetal Goat Model.

CNS Neurosci Ther

December 2024

Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, NHC Key Laboratory of Chronobiology, Sichuan University, Chengdu, China.

Background: Preterm white matter injury (PWMI) is the most common type of brain injury in preterm infants, in which, oligodendrocyte progenitor cells (OPCs) are predominantly damaged. In this study, human OPCs (hOPCs) were administered to a fetal goat model of PWMI to examine the differentiation potential and therapeutic effects of the cells on PWMI.

Methods: Preterm goat fetuses were subjected to hypoxic-ischemia (HI) via intermittent umbilical cord occlusion (5 min × 5).

View Article and Find Full Text PDF

Feasibility and safety of autologous cord blood derived cell administration in extremely preterm infants: a single-centre, open-label, single-arm, phase I trial (CORD-SaFe study).

EBioMedicine

December 2024

Monash Newborn, Monash Children's Hospital, Melbourne, Australia; Department of Paediatrics, Monash University, Melbourne, Australia; The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Australia. Electronic address:

Background: Evidence from preclinical studies in small and large animal models has shown neuroprotective effects of intravenous administration of umbilical cord blood derived cells (UCBCs). This study aimed to evaluate the feasibility of umbilical cord blood (UCB) collection, extraction of UCBCs, and subsequent safety of intravenous autologous administration of UCBCs in extremely preterm infants (born <28 weeks gestation).

Methods: A single-centre, open-label, single-arm, safety and feasibility clinical intervention trial was conducted at Monash Medical Centre and Monash Children's Hospital, Melbourne, Australia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!